All News

Kidneys small

Sooner May Still Be Too Late: Kidney Biopsies in SLE

d Michael Putman, MD, MSCI

ACR Convergence 2025 will be kicking off with a Plenary Session by Michelle Petri (Abstract 0772: Redefining When to Biopsy the Kidney in Patients with SLE), which is a great place to kick off our coverage of the meeting. As part of a collaboration with the Accelerating Medicines Partnership, Petri and colleagues have given data to what many of us have long suspected: a biopsy threshold of 0.5g/d of proteinuria may be too high.

Read Article
Sleep asleep

Sleep Apnea in Psoriatic Arthritis – A Wake Up Call

d Antoni Chan, MD, PhD

Fatigue is one of the most disabling symptoms in psoriatic arthritis (PsA), yet its causes are often underexplored. At ACR 2025, Abstract #0549, a possible hidden contributor was studied: obstructive sleep apnea (OSA).

Read Article
Red puzzle piece

New pieces added to the Pre-RA puzzle

d Aurelie Najm, MD, PhD

We know that pre-RA is a definition that stands under a large umbrella, ranging from asymptomatic individuals with ACPA positivity to individuals with symptomatic pre-clinical synovitis. How can we predict the transition from the at-risk state to clinical RA outside the realm of clinical, conventional serological (RF/anti-CCP) or imaging (US/MRI synovitis) biomarkers?

Read Article
ANCA, vasculitis, test

Mimics of ANCA-associated vasculitis: How can we tell?

d Brian Jaros, MD

With increased disease awareness and more regular, accessible testing for anti-neutrophil cytoplasmic antibodies (ANCA), ANCA-associated vasculitis (AAV) has become an increasingly recognized clinical entity in rheumatologic practice. 

Read Article
RheumNow Podcast square

Pre-ACR25 (10.24.2025)

d Jack Cush, MD

Dr. Jack Cush reviews the news and info reports the day before ACR 2025

Read Article
woman,doctor,stress,burnout,headache,HA

Stress Raises the Risk of Psoriasis

d EurekAlert!

New longitudinal research reveals that severe stress caused by changes in family structure like divorce or separation experienced during the first year of life may triple the risk of developing psoriasis later in life.

Read Article
Rheum guidelines balance data & context. Beyond evidence, factors like cost, equity & feasibility shape recs. GRADE-ADOLOPMENT = global tool to adopt, adapt, or design local guidance for more rapid integration and with less $$$ @RheumNow #ACR25 #GlobalRheumSummitt https://t.co/Sfsqxsqpt4

Links:

Jiha Lee JihaRheum ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 Annual Meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

12 yr study of 115 Systemic Sclerosis pts shows Finger-to-palm distance (tip 4th finger to distal palmar crease) may be a useful tool for predicting the progression of skin thickening and the development of digital ulcers in the early stages of severe SSc https://t.co/brCEz5Fqac https://t.co/kZMQ0UsimB

Links:

Dr. John Cush RheumNow ( View Tweet)
From Eye on Cytokine Storm- Decoding MAS by Dr Grant Schulert : “IL-18 is highly elevated in SJIa and other autoinflammatory disorders…can amplify innate signaling as well as induce IFN-gamma”. @RheumNow #ACR2025 https://t.co/6e5yfeDepX

Links:

Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
🔥 Hot off the press Prof John Stone shares results from Phase 3 of REPLENISH, out only a few days ago, in which secukinumab met all primary endpoints in treatment of PMR. https://t.co/RlcQWybKrR #ACR25 @RheumNow https://t.co/ucNt2HxJpW

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Summary of updates in Vasculitis by Dr John Stone: 1. Anti-CD19 in IgG4Rd, 2. IL6 6R blockade in GCA/IL17i in PMR, 3. IL5RA+ ritux in EGPA. CART in AAV? @RheumNow #ACR2025 https://t.co/HxPNRE98Vl

Links:

Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
Telitacicept Effective in Systemic Lupus Erythematosus The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few https://t.co/L0TgynLELD
Dr. John Cush RheumNow ( View Tweet)
FDA has approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy. https://t.co/0eGwGnSDYf https://t.co/wnQDVnTEjb

Links:

Dr. John Cush RheumNow ( View Tweet)
Great to be with team @RheumNow reporting on the latest from #ACR25 https://t.co/h941qYSc6U

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

Casal Moura, M., Merkel, P.A., Jayne, D. et al.Challenges in the diagnosis, classification and prognosis of ANCA-associated vasculitis. Nat Rev Rheumatol (2025). https://t.co/fGUr2DnfwA Good figure, citation above. Via @AKronbichler and colleagues https://t.co/FGfPFiGgMv

Links:

Suleman Bhana, MD DrBhana ( View Tweet)

Clinical and Genetic Effects of Neuropsychiatric Lupus The clinical features and genetic abnormalities of neuropsychiatric systemic lupus erythematosus shows that NPSLE often means more severe lupus and more organ involvement beyond the central nervous system. https://t.co/7Ujo6Kaf1N
Dr. John Cush RheumNow ( View Tweet)
REPLENISH - Secukinumab Works in Polymyalgia Rheumatica Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab (Cosentyx) (SEC) in adults with polymyalgia rheumatica (PMR). https://t.co/qa9RzmNFU4 https://t.co/dCEkelJzni

Links:

Dr. John Cush RheumNow ( View Tweet)
Colchicine Ineffective in Long COVID Management of long COVID has been perplexing with symptoms having functional and possibly inflammatory origins. Colchicine has been studied in long COVID and failed to improve functional capacity, respiratory function, or inflammatory https://t.co/9E3dvUFqJP
Dr. John Cush RheumNow ( View Tweet)
SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease SGLT-2 inhibitors offer benefits beyond glycemic control, such as cardioprotective and nephroprotective effects, and modest weight loss. A recent study also suggests they may have immunomodulatory effects and https://t.co/O4Pi8GyT32
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×